-
2024-514352-32-00
10
2023-01-03
Acute ischemic stroke
-
2022-502078-17-00
4
2022-12-15
unresectable hepatocellular carcinoma
-
2024-513651-32-00
4
2022-11-10
Juvenile Dermatomyositis
-
2024-514419-93-00
9
2022-05-19
Study to investigate the safety and efficacy of GB1211 (a galectin-3 i
-
2023-509139-16-00
5
2022-05-13
Therapeutic confirmatory (phase III)
-
2023-509784-24-00
4
2022-05-11
Idiopathic Pulmonary Fibrosis
-
2023-508820-37-00
5
2022-02-03
Cytomegalovirus Infection (CMV)
-
2024-514570-43-00
5
2022-01-24
Renal cell carcinoma
-
2024-513707-14-00
5
2022-01-14
Only patients with oncologic locally advanced or metastatic tumour (lu
-
2024-513672-17-00
4
2021-06-14
Inoperable Chronic thromboembolic pulmonary hyperTension
-
2022-501188-42-00
4
2021-04-15
Early Alzheimer's Disease
-
2024-517839-50-00
11
2020-09-20
sepsis
-
2024-516670-29-00
4
2020-09-15
Multiple Myeloma
-
2024-516407-16-00
5
2020-04-10
Patients admitted to the ICU proven or suspected infection as the main
-
2024-515955-39-01
4
2020-02-04
Lingual microcystic lymphatic malformations (LMLMs) are rare congenita
-
2024-514889-40-00
6
2019-12-20
Hyperkalemia
-
2024-512537-33-00
5
2019-11-28
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
-
2022-502886-71-00
5
2019-11-20
Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA N
-
2023-507669-24-00
5
2019-11-05
Chronic lymphocytic leukemia
-
2024-514586-20-01
5
2018-05-02
Non small cell lung cancer
-
2024-511967-26-00
5
2016-11-21
AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)
-
2023-507294-18-00
5
2016-09-16
Metastatic renal cell carcinoma
-
2024-517856-36-00
5
2015-03-09
Completely resected primary stage IB (≥ 4cm), II and IIIA non-small ce
-
2023-507291-52-00
4
2014-03-24
Extranodal Marginal Zone Lymphoma